Professor of Medicine Washington University in St. Louis
Oncology
Dr. Bruce J. Roth, MD
|
|
Give Review
Dr. Bruce J. Roth is an expert in the field of Oncology. He attended Saint Louis University School of Medicine. Saint Louis University School of Medicine has a rank of 67 in research and a 57 in primary care He received awards:"America's Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification", "Fellow (FASCO)" and "Nashville Lifestyles Magazine". Bruce J. Roth, MD is also a published MD. He has 35 publication published. The most recent publication is: Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
Publications
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
- Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
- Active surveillance is the preferred approach to clinical stage I testicular Cancer.
- Castration-Resistant Prostate Cancer: AUA Guideline.
- Prostate-specific antigen test for prostate Cancer screening: american society of clinical oncology provisional clinical opinion.
- Clinical Cancer advances 2012: annual report on progress against Cancer from the american society of clinical oncology.
- Screening for prostate Cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion.
- Classical clinical trial design in testicular Cancer: time to move on.
- Clinical Cancer Advances 2011: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
- A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with met...
- NCCN clinical practice guidelines in oncology: prostate Cancer.
- Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.
- Phase 2 trial of sorafenib in patients with advanced urothelial Cancer: a trial of the Eastern Cooperative Oncology Group.
- A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies.
- Prostate Cancer serum biomarker discovery through proteomic analysis of alpha-2 macroglobulin protein complexes.
- Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial Cancer (E4802): a trial of the Eastern Cooperative Oncology Group.
- Phase 2 trial of epothilone B Analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group.
- Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone...
- Adjuvant weekly docetaxel for patients with high risk prostate Cancer after radical prostatectomy: a multi-institutional pilot study.
- Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate Cancer.
- Sperm banking: use and outcomes in patients treated for testicular Cancer.
- Management of recurrent testicular germ Cell tumors.
- Phase II study of pemetrexed for second-line treatment of transitional cell Cancer of the urothelium.
- Changing perspectives of the role of chemotherapy in advanced prostate Cancer.
- Phase II study of carboxyamidotriazole in patients with advanced renal Cell carcinoma refractory to immunotherapy: E4896, an Eastern Cooperative Oncology Group Study.
- Performance-enhancing supplement use in patients with testicular Cancer.
- Prostate Cancer chemotherapy: emerging from the shadows.
- Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced Carcinoma of the urothelium.
- A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid Tumors.
- Phase II trial of gemcitabine and docetaxel in patients with advanced Carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group.
- Overview of advanced urothelial Cancer trials of the Eastern Cooperative Oncology Group.
- Piritrexim in advanced, refractory Carcinoma of the urothelium (E3896): a phase II trial of the Eastern Cooperative Oncology Group.
- Beneficial impact of a clinical care pathway in patients with testicular Cancer undergoing retroperitoneal lymph node dissection.
- Treatment of clinical stage I germ Cell tumors.
Schools
Saint Louis University School Of Medicine
Clarian Indiana University Hospital
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Anthem Blue Cross Blue Shield PPO
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Coventry Health Care of Illinois PPO
- Coventry Health Care of Kansas, Inc. PPO
- Coventry Health Care of Missouri PPO
- First Health (Coventry Health Care) PPO
- HealthLink PPO
- Homestate Health Plan
- Choice Care PPO
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Fellow (FASCO)
- Nashville Lifestyles Magazine
Education
-
Indiana University School of Medicine -
Saint Louis University School of Medicine
Hospital
-
Barnes-Jewish Hospital
Drug Facts
| NPI NUMBER | 1740496660 | |
| NPPES Provider LastName | ROTH | |
| NPPES Provider FirstName | BRUCE | |
| NPPES Provider ZIPCode | 631101032 | |
| NPPES Provider State | MO | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 711.0 | |
| Distinct Opioid Count | 5.0 | |
| Opioid Claim Count | 139.0 | |
| Percent Opioid Claims | 19.55 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1740496660 |
| Last Name Of The Provider | ROTH |
| First Name Of The Provider | BRUCE |
| View All |
Similar Doctors
|
|
Dr. Nancy L. Bartlett, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Mary M. Klix, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Douglas R. Adkins, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sagun D. Goyal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Albert C. Lockhart, MD |
|
|
Dr. Iskra Pusic, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ravi Vij, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Ryan C. Lynch, MD
This Doctor is OpenDoctor Recommended.
|